These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1683552)

  • 1. The effect of repeated oral doses of lornoxicam on antipyrine elimination in normal human volunteers.
    Ravic M; Johnston A; Turner P; Takacs F; Rosenow DE
    Hum Exp Toxicol; 1991 Sep; 10(5):375-7. PubMed ID: 1683552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation.
    Warrington SJ; Lewis Y; Dawnay A; Johnston A; Kovacs IB; Lamb E; Ravic M
    Postgrad Med J; 1990; 66 Suppl 4():S35-40. PubMed ID: 2284219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of the interaction between lornoxicam and warfarin in healthy volunteers.
    Ravic M; Johnston A; Turner P; Ferber HP
    Hum Exp Toxicol; 1990 Nov; 9(6):413-4. PubMed ID: 2271233
    [No Abstract]   [Full Text] [Related]  

  • 4. Impairment of human antipyrine metabolism by piroxicam.
    Battellino LJ; Dorronsoro de Cattoni ST; Ragagnin C
    Can J Physiol Pharmacol; 1990 Jun; 68(6):711-7. PubMed ID: 2372742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.
    Ravic M; Johnston A; Turner P
    Postgrad Med J; 1990; 66 Suppl 4():S30-4. PubMed ID: 2126624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of lornoxicam in man.
    Hitzenberger G; Radhofer-Welte S; Takacs F; Rosenow D
    Postgrad Med J; 1990; 66 Suppl 4():S22-7. PubMed ID: 2284217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1997 Jun; 47(6):755-7. PubMed ID: 9239455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety of lornoxicam in G-6-PDH deficiency].
    Perpignano G; Cacace E; Matulli C; Ruggiero V
    Reumatismo; 2003; 55(1):45-7. PubMed ID: 12649700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analgesic activity of cinnoxicam. Findings of clinical sensimetry].
    Biasi G; Piazzini M; Fioravanti A; Francioni C; Marcolongo R
    Clin Ter; 1989 Dec; 131(5):315-9. PubMed ID: 2532585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of tenoxicam on tolbutamide pharmacokinetics and glucose concentrations in healthy volunteers.
    Day RO; Geisslinger G; Paull P; Williams KM
    Int J Clin Pharmacol Ther; 1995 May; 33(5):308-10. PubMed ID: 7655772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of lornoxicam on serum pepsinogen levels.
    Kullich W; Klein G; Pöllmann G
    Postgrad Med J; 1990; 66 Suppl 4():S46-8. PubMed ID: 2149454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics.
    Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
    Eur J Clin Pharmacol; 1999 Jan; 54(11):857-64. PubMed ID: 10027661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics.
    Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
    Eur J Clin Pharmacol; 1999 Jan; 54(11):865-8. PubMed ID: 10027662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of repeated oral doses of azelastine hydrochloride on antipyrine half-life in normal volunteers.
    Johnston A; Warrington SJ; Turner P; Aurich R
    J Pharm Pharmacol; 1988 Mar; 40(3):225. PubMed ID: 2899161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of lornoxicam on the physiology of severe sepsis.
    Memiş D; Karamanlioğlu B; Turan A; Koyuncu O; Pamukçu Z
    Crit Care; 2004 Dec; 8(6):R474-82. PubMed ID: 15566594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of lornoxicam for analgesia in the early postoperative period].
    Nikoda VV; Maiachkin RB; Bondarenko AV; Mikhaĭlov IuE; Anosova NP
    Anesteziol Reanimatol; 2001; (6):47-50. PubMed ID: 11855063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of lornoxicam in human plasma by LC/MS/MS].
    Zeng YL; Chen XY; Zhang YF; Zhong DF
    Yao Xue Xue Bao; 2004 Feb; 39(2):132-5. PubMed ID: 15127622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
    Kohl C; Steinkellner M
    Drug Metab Dispos; 2000 Feb; 28(2):161-8. PubMed ID: 10640513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous pseudolymphoma following administration of lornoxicam.
    Stavrianeas NG; Katoulis AC; Bozi E; Toumbis-Ioannou E; Kanelleas AI; Makris M; Kalogeromitros D; Panayiotides I
    Acta Derm Venereol; 2007; 87(5):453-5. PubMed ID: 17721665
    [No Abstract]   [Full Text] [Related]  

  • 20. A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects.
    Soto J; Alsar MJ
    J Clin Pharm Ther; 1997 Jun; 22(3):191-5. PubMed ID: 9447474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.